X
Pfizer objects to NICE methods in leukaemia drug rejection
https://pharmaphorum.com/news/pfizer-questions-nice-methods-besponsa/
ALL
Pfizer’s fast-tracked leukaemia candidate could rival CAR-Ts
Antibody-drug conjugate with FDA gets six-month review.